Researchers have discovered a surprising relationship between belly fat and painful psoriasis, a chronic inflammatory skin condition.
Studies have shown that obesity is a risk factor for psoriasis, but never before have scientists established the waist and belly to be the most influential places.
Psoriasis and obesity, which affects around 100 million American adults, share the same organic route: chronic inflammation. Adipose (fat) tissue releases inflammatory chemicals that collide with the immune system, which can cause inflammation in the skin, and psoriasis’ trademark red, flaky rash.
The team of dermatologists of King’s College London analyzed data from more than 330,000 white people who live in the UK, including more than 9,000 with psoriasis, who affects around 7.5 million Americans.
They investigated 25 different body fat measures with the help of traditional methods, such as calipers that squeeze skin folds, and advanced imaging techniques, such as highly specialized X -ray scans, with which they were assessed how each was associated with psoriasis.
Researchers discovered that the waist hip ratio against a person was the strongest risk factor for psoriasis, but did not reveal why specific fat had the strongest association.
Dr. RAVI Ramessur, lead researcher in the study, said: ‘Our research shows that where fat is stored in the body matters when it comes to the risk of psoriasis. Central – fat – especially around the waist – seems to play a key role.
“This has important implications for how we identify individuals who are more likely to develop psoriasis or experience more serious illness, and how we approach prevention and treatment strategies.”
Psoriasis is a car -immune skin condition that produces inflammatory chemicals, leading to a red, painful rash on the skin (stock image)
The researchers measure the overall ‘central’ fat around the hull and include subcutaneous fat directly under the skin surface and dangerous visceral fat that wraps itself around the organs.
The relationship between central fat and psoriasis remained consistent regardless of genetic predisposition, indicating that belly fat is an independent risk factor.
Dr. Catherine Smith, senior author, said: ‘As obesity percentages continue to rise, it is important to understand how different patterns of body fat chronic inflammatory disorders such as psoriasis influence.
‘Our findings suggest that central body fat contributes to psoriasis risk, regardless of genetic predisposition and the importance of measuring waist circumference and proactive healthy weight strategies in psoriasis care. “
In addition to releasing inflammatory connections, fatty tissue hits the balance of hormones of the body.
The hormone leptin normally indicates on the brain, the body is full and it’s time to stop eating.
But fat cells produce this hormone over produce and break that ‘stop eating’ signal.
The obesity rate in American adults rose from 21.2 percent in 1990 to 43.8 percent in 2022 for women and 16.9 percent to 41.6 percent for men
The overflow of leptin also stimulates the production of inflammatory cytokines, which leads to a psoriasis breakout of painful rash and subsequent flare-ups in the skin.
In a related main article, Dr. Joel Gelfand, a dermatology expert at the University of Pennsylvania, the promise of specific intestinal hormone therapies, at least GLP-1 and GIP, who help the blood sugar, digestion and hunger to control potential therapies for psoriatic disorders.
These hormones, sold under brands such as Ozmepic, Wegovy and Zepbound, are already used to treat diabetes, obesity and obesity-related sleep apnea.
A separate NIH-Fastinanced report from 2024 in the magazine Psoriasis analyzed four studies with 23 patients with both psoriasis and type 2 diabetes that took a GLP-1 receptor agency senior agent.
Each study showed significant reductions in Pasi scores, a measure of the severity of psoriasis.
Two studies showed fewer markers of inflammation in skin layers and reduced harmful immune response.
Patients also reported an improved quality of life.
Scientists discovered that the relationship between fat in the risk of the abdomen and psoriasis was consistent, regardless of whether the people had a genetic predisposition
Now that researchers are investigating whether the medicines can also help in managing psoriatic disease, possibly by tackling inflammation and metabolic problems related to psoriasis.
According to Dr. Gelfand, the powerful link between obesity and psoriasis, as well as the proof that GLP-1 drugs can alleviate the symptoms, it indicates time to launch clinical examinations that test the medicines specifically for psoriasis.
He said: ‘The strong relationship between psoriasis and obesity and the emerging promise of glucagon-like peptide-1 receptoragonists (GLP1RA) for reducing psoriasis morbidity is a call for action for large-scale clinical tests of GLP1RA monotherapy for psoriasis treatment.
“Our current paradigm of just focusing on skin and joint manifestations in treating psoriasis is outdated in the context of our evolving understanding of the tight relationship of psoriasis, obesity and cardiometabolic disease.”
#Strange #link #discovered #painful #skin #disease #stubborn #belly #fat